Oncolytics Biotech Inc.
ONC.TO
TSX
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | -18.46% | -13.13% | 23.15% | 29.15% | 35.36% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 1.98% | 4.87% | 27.24% | 28.68% | 21.42% |
| Operating Income | -1.98% | -4.87% | -27.24% | -28.68% | -21.42% |
| Income Before Tax | -12.26% | 15.52% | -3.58% | -13.69% | -8.27% |
| Income Tax Expenses | 31.75% | 33.58% | 35.29% | 13.79% | 13.79% |
| Earnings from Continuing Operations | -12.33% | 15.35% | -3.70% | -13.69% | -8.28% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -12.33% | 15.35% | -3.70% | -13.69% | -8.28% |
| EBIT | -1.98% | -4.87% | -27.24% | -28.68% | -21.42% |
| EBITDA | -1.92% | -4.81% | -27.30% | -28.79% | -21.55% |
| EPS Basic | 1.69% | 28.41% | 13.19% | 3.27% | 6.14% |
| Normalized Basic EPS | 1.77% | 28.54% | 13.30% | 3.22% | 6.08% |
| EPS Diluted | 1.69% | 28.41% | 13.19% | 3.27% | 6.14% |
| Normalized Diluted EPS | 1.77% | 28.54% | 13.30% | 3.22% | 6.08% |
| Average Basic Shares Outstanding | 13.13% | 17.96% | 20.55% | 19.11% | 16.51% |
| Average Diluted Shares Outstanding | 13.13% | 17.96% | 20.55% | 19.11% | 16.51% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |